This is a year -25 renewal request that addresses a recognized challenge in medicinal inorganic chemistry, namely moving beyond platinum in oncology. To do this, a set of texaphyrin-gold conjugates is proposed. These systems will help overwhelm the antioxidant defense network essential to tumor growth via two overlapping mechanisms. They will also build on progress made in recent years under this grant that has led to very promising texaphyrin-platinum conjugates that display improved efficacy and reduced toxicity relative to FDA-approved agents, such as oxaliplatin. However, this proposal addresses a new challenge, namely using texaphyrins to deliver gold(I) N-heterocyclic carbene complexes to tumors. There is a strong mechanistic rationale for doing so. We have recently shown that uniquely designed, N-hetrocyclic carbene Au(I) complexes give rise to enhanced inhibition of antioxidant activity in cancer models as a result of thioredoxin reductase (TrxR) inhibition. On the other hand, texaphyrins are known to increase oxidative stress through redox cycling. This complementarity is unique and exciting. It should allow us to target the antioxidant protective network from two different directions and do so in a tumor-selective manner. To test the promise inherent in this hypothesis, we will pursue the following specific aims:
Aim 1. Synthesize texaphyrin-Au(I) conjugates containing both labile and non-labile linkages. Use N- heterocyclic carbenes to control gold complexation.
Aim 2. Assess the ability of the texaphyrin-Au conjugates to affect the antioxidant network. Use MTT assays to assess anti-proliferation activity in well-studied cancer cell lines and use flow cytometry to screen for oxidative stress response.
Aim 3. Study texaphyrin-Au conjugate cellular uptake and compartmentalization in vitro. Use analyses of metal content (Gd, Au) and LCMS measurements of texaphyrin concentration in cellular and organ digests to confirm whole cell uptake and subcellular localization.
Aim 4. Begin studies of toxicity and efficacy in vivo. Use murine models to determine the tolerability and biodistribution of the most promising texaphyrin-Au conjugates and their ability to localize to solid tumors and inhibit tumor growth in vivo.

Public Health Relevance

This ongoing project addresses a major challenge in medicinal inorganic chemistry, namely going beyond platinum in oncology. Building off success with platinum constructs, new gold-texaphyrin conjugates are proposed. They target the antioxidant defense systems of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA068682-25
Application #
9307322
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Kondapaka, Sudhir B
Project Start
1990-08-01
Project End
2022-02-28
Budget Start
2017-03-08
Budget End
2018-02-28
Support Year
25
Fiscal Year
2017
Total Cost
$360,416
Indirect Cost
$122,916
Name
University of Texas Austin
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
170230239
City
Austin
State
TX
Country
United States
Zip Code
78712
Jung, Hyo Sung; Verwilst, Peter; Sharma, Amit et al. (2018) Organic molecule-based photothermal agents: an expanding photothermal therapy universe. Chem Soc Rev 47:2280-2297
Lee, Min Hee; Sharma, Amit; Chang, Min Jung et al. (2018) Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics. Chem Soc Rev 47:28-52
Jung, Hyo Sung; Lee, Jae-Hong; Kim, Kyutae et al. (2017) A Mitochondria-Targeted Cryptocyanine-Based Photothermogenic Photosensitizer. J Am Chem Soc 139:9972-9978
Jung, Hyo Sung; Han, Jiyou; Shi, Hu et al. (2017) Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach. J Am Chem Soc 139:7595-7602
Shin, Weon Sup; Han, Jiyou; Kumar, Rajesh et al. (2016) Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor. Sci Rep 6:29018
Thiabaud, Gregory; McCall, Rebecca; He, Guangan et al. (2016) Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angew Chem Int Ed Engl 55:12626-31
Arambula, J F; McCall, R; Sidoran, K J et al. (2016) Targeting Antioxidant Pathways with Ferrocenylated N-Heterocyclic Carbene Supported Gold(I) Complexes in A549 Lung Cancer Cells. Chem Sci 7:1245-1256
Zhang, Huacheng; Lee, Juhoon; Lammer, Aaron D et al. (2016) Self-Assembled Pyridine-Dipyrrolate Cages. J Am Chem Soc 138:4573-9
Brown, Katherine A; Yang, Xiaoping; Schipper, Desmond et al. (2015) A self-assembling lanthanide molecular nanoparticle for optical imaging. Dalton Trans 44:2667-75
Lee, Min Hee; Kim, Jong Seung; Sessler, Jonathan L (2015) Small molecule-based ratiometric fluorescence probes for cations, anions, and biomolecules. Chem Soc Rev 44:4185-91

Showing the most recent 10 out of 51 publications